Rx0000105 |
Takeda Pharmaceuticals America, Inc. |
03/31/2022 |
64764030020 |
Entyvio 300mg 20mL Vial |
01/04/2022 |
436.60 |
7713.23 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired in the last 5 years. Please note that Patent Expiration Date is not publicly available for Entyvio. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ |
Rx0000232 |
TerSera Therapeutics LLC |
03/31/2022 |
70720012585 |
(New Labeler Code) XERMELO (telostristat ethyl), Oral Tablet, 250mg, 1 Case/84 Tablets |
01/01/2022 |
370.52 |
7932.07 |
02/27/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/08/2020 |
Lexicon Pharmaceuticals, Inc |
159000000 |
None |
" Lexicon received approximately $159M in upfront payments and up to $65 million in future milestone payments plus mid-teens royalties on net sales of XERMELO for the treatment of biliary tract cancer." |
6559.00 |
5961.00 |
2017 |
5164.00 |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
This product's NDC description matches another product inside this manufacturers submissions, but the NDCs are different. This is due to the manufacturer acquiring the product and then changing the NDC to their labeler code in the past few months. |
Rx0000232 |
TerSera Therapeutics LLC |
03/31/2022 |
70720095036 |
ZOLADEX (goserelin implant), 3.6mg, 1 Syringe |
01/01/2022 |
36.60 |
783.61 |
04/13/2022 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/06/2018 |
AztraZeneca |
320000000 |
None |
AstraZeneca received a $250m upfront payment for the rights of Zoladex, with double-digit quarterly sales-based payments being recieved on an ongoing basis. A further $70m was also in the sell should Zoladex meet a series of sales-related milestones |
605.00 |
550.50 |
1989 |
265.63 |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. |
Rx0000217 |
Teva Neuroscience, Inc. |
03/31/2022 |
68546017260 |
AUSTEDO TABLETS 12MG 60 |
01/01/2022 |
485.37 |
6629.90 |
09/15/2038 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000217 |
Teva Neuroscience, Inc. |
03/31/2022 |
68546017060 |
AUSTEDO TABLETS 6MG 60 |
01/01/2022 |
323.60 |
4419.90 |
09/15/2038 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000217 |
Teva Neuroscience, Inc. |
03/31/2022 |
68546017160 |
AUSTEDO TABLETS 9MG 60 |
01/01/2022 |
364.10 |
4972.40 |
09/15/2038 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000217 |
Teva Neuroscience, Inc. |
03/31/2022 |
68546014256 |
AZILECT TABLET 0.5MG 30 |
01/01/2022 |
85.60 |
996.50 |
08/27/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000217 |
Teva Neuroscience, Inc. |
03/31/2022 |
68546022956 |
AZILECT TABLET1MG 30 |
01/01/2022 |
85.60 |
996.50 |
08/27/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459051230 |
ACTIQ Lozenge 1200MCG 30 |
01/01/2022 |
537.60 |
6256.40 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459051630 |
ACTIQ Lozenge 1600MCG 30 |
01/01/2022 |
663.20 |
7718.10 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459050230 |
ACTIQ Lozenge 200MCG 30 |
01/01/2022 |
225.30 |
2621.60 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459050430 |
ACTIQ Lozenge 400MCG 30 |
01/01/2022 |
285.10 |
3318.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459050830 |
ACTIQ Lozenge 800MCG 30 |
01/01/2022 |
413.60 |
4813.20 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459050630 |
ACTIQ Lozenge 600MCG 30 |
01/01/2022 |
349.40 |
4066.40 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
57844011001 |
ADDERALL TABLET 10MG 100 |
01/01/2022 |
77.03 |
896.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
57844012001 |
ADDERALL TABLET 20MG 100 |
01/01/2022 |
77.03 |
896.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
57844013001 |
ADDERALL TABLET 30MG 100 |
01/01/2022 |
77.03 |
896.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
57844011201 |
ADDERALL TABLET12.5MG 100 |
01/01/2022 |
77.03 |
896.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
57844011501 |
ADDERALL TABLET15MG 100 |
01/01/2022 |
77.03 |
896.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
57844010501 |
ADDERALL TABLET5MG 100 |
01/01/2022 |
77.03 |
896.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
57844011701 |
ADDERALL TABLET7.5MG 100 |
01/01/2022 |
77.03 |
896.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459070060 |
AMRIX ORAL CAPSULE ER 15 MG 60 |
01/01/2022 |
260.70 |
3034.50 |
02/26/2025 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459070160 |
AMRIX ORAL CAPSULE ER 30 MG 60 |
01/01/2022 |
260.70 |
3034.50 |
02/26/2025 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459054128 |
FENTORA TABLET 100MCG 28 |
01/01/2022 |
164.90 |
1918.90 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459054228 |
FENTORA TABLET 200MCG 28 |
01/01/2022 |
208.30 |
2424.40 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459054428 |
FENTORA TABLET 400MCG 28 |
01/01/2022 |
302.30 |
3517.80 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459054628 |
FENTORA TABLET 600MCG 28 |
01/01/2022 |
392.40 |
4567.00 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459054828 |
FENTORA TABLET 800MCG 28 |
01/01/2022 |
483.40 |
5626.40 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
52544008001 |
FIORICET CAPSULE 50/300/40MG 100 |
01/01/2022 |
56.00 |
652.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
52544008201 |
FIORICET/CODEINE CAPSULE 50/300/40/30MG 100 |
01/01/2022 |
117.30 |
1365.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
00093360882 |
FLUTIC/SALMET INH PWD 113/14MCG 60 DOSE |
02/07/2022 |
21.60 |
117.00 |
04/06/2035 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
00093360982 |
FLUTIC/SALMET INH PWD 232/14MCG 60 DOSE |
02/07/2022 |
21.60 |
117.00 |
04/06/2035 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
00093360782 |
FLUTICA/SALMET INH PWD 55-14MCG 60 DOSE |
02/07/2022 |
21.60 |
117.00 |
04/06/2035 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459041230 |
GABITRIL TABLET 12MG 30 |
01/01/2022 |
39.70 |
461.90 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459040230 |
GABITRIL TABLET 2MG 30 |
01/01/2022 |
30.70 |
357.30 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459040430 |
GABITRIL TABLET 4MG 30 |
01/01/2022 |
30.70 |
357.30 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459041630 |
GABITRIL TABLET16MG 30 |
01/01/2022 |
52.00 |
604.80 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
57844021552 |
GALZIN CAPSULE 25MG 250 |
01/01/2022 |
40.70 |
474.10 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
57844020852 |
GALZIN CAPSULE 50MG 250 |
01/01/2022 |
67.90 |
790.10 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
16252053901 |
ISRADIPINE 2.5MG CAPSULES 100 |
01/17/2022 |
47.40 |
144.30 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
16252054001 |
ISRADIPINE 5MG CAPSULES 100 |
01/17/2022 |
69.29 |
211.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459021530 |
NUVIGIL TABLET 150MG 30 |
01/01/2022 |
87.10 |
1013.50 |
06/18/2024 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459022030 |
NUVIGIL TABLET 200MG 30 |
01/01/2022 |
87.10 |
1013.50 |
06/18/2024 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459022530 |
NUVIGIL TABLET 250MG 30 |
01/01/2022 |
87.10 |
1013.50 |
06/18/2024 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459020530 |
NUVIGIL TABLET 50MG 30 |
01/01/2022 |
28.90 |
336.80 |
06/18/2024 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
00575620030 |
PROGLYCEM ORAL SUSPENSION 50MG/ML 30ML/ 1 BOTTLE |
01/01/2022 |
32.40 |
376.80 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459010130 |
PROVIGIL TABLET 100MG 30 |
01/01/2022 |
121.90 |
1418.30 |
05/29/2024 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459020130 |
PROVIGIL TABLET 200MG 30 |
01/01/2022 |
184.10 |
2142.90 |
05/29/2024 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459017714 |
SYNRIBO INJECTION 3.5 MG |
01/01/2022 |
104.50 |
1216.50 |
10/26/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2022 |
63459060106 |
TRISENOX VIAL 2 MG/ML 6 ML |
01/01/2022 |
916.30 |
10663.80 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000218 |
Teva Respiratory, LLC |
03/31/2022 |
59310081206 |
AIRDUO 113-14MCG 60 ACT /inhaler |
01/01/2022 |
32.97 |
383.30 |
04/06/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000218 |
Teva Respiratory, LLC |
03/31/2022 |
59310082206 |
AIRDUO 232-14MCG 60 ACT/ inhaler |
01/01/2022 |
32.97 |
383.30 |
04/06/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000218 |
Teva Respiratory, LLC |
03/31/2022 |
59310080506 |
AIRDUO 55-14MCG 60 ACT /inhaler |
01/01/2022 |
32.97 |
383.30 |
04/06/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000218 |
Teva Respiratory, LLC |
03/31/2022 |
59310040606 |
QNASL PLV INHALER 40MCG 60/ACT TRADE /1 inhaler |
01/01/2022 |
24.21 |
281.73 |
10/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000218 |
Teva Respiratory, LLC |
03/31/2022 |
59310041012 |
QNASL PLV INHALER 80MCG 120/ACT TRADE/ 1 inhaler |
01/01/2022 |
24.21 |
281.73 |
10/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000219 |
Teva Women's Health, Inc. |
03/31/2022 |
51285042410 |
AYGESTIN TABLET 5MG 50 |
01/01/2022 |
26.10 |
303.30 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000219 |
Teva Women's Health, Inc. |
03/31/2022 |
51285012870 |
LOESTRIN FE TABLET 28 1.5MG/30MCG 140 |
01/01/2022 |
72.40 |
842.10 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000219 |
Teva Women's Health, Inc. |
03/31/2022 |
51285012570 |
LOESTRIN FE TABLET 28 1MG/20MCG 140 |
01/01/2022 |
72.40 |
842.10 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000219 |
Teva Women's Health, Inc. |
03/31/2022 |
51285013197 |
LOESTRIN TABLET 21 1.0MG/20MCG 105 |
01/01/2022 |
72.40 |
842.10 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000219 |
Teva Women's Health, Inc. |
03/31/2022 |
51285012797 |
LOESTRIN TABLET 21 1.5MG/30MCG 105 |
01/01/2022 |
72.40 |
842.10 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000219 |
Teva Women's Health, Inc. |
03/31/2022 |
51285009287 |
LOSEASONIQUE TABLET 0.1-0.02 & 0.01 MG 182 |
01/01/2022 |
84.10 |
979.20 |
12/05/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000219 |
Teva Women's Health, Inc. |
03/31/2022 |
51285012058 |
MIRCETTE TABLET 28 .15MG/.02MG .01MG |
01/01/2022 |
90.70 |
1055.10 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000219 |
Teva Women's Health, Inc. |
03/31/2022 |
51285006390 |
PREFEST TABLET 1/1-0.09 MG 180 |
01/01/2022 |
92.30 |
1074.70 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000219 |
Teva Women's Health, Inc. |
03/31/2022 |
51285043187 |
QUARTETTE TABLET 42-21-21-7 DAYS 182 |
01/01/2022 |
100.80 |
1172.70 |
03/11/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000219 |
Teva Women's Health, Inc. |
03/31/2022 |
51285008787 |
SEASONIQUE TABLET 0.15-0.03 &0.01 MG 182 |
01/01/2022 |
84.10 |
979.20 |
12/05/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000219 |
Teva Women's Health, Inc. |
03/31/2022 |
51285036801 |
TREXALL TABLET 10MG 30 |
01/01/2022 |
90.80 |
1056.90 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000219 |
Teva Women's Health, Inc. |
03/31/2022 |
51285036901 |
TREXALL TABLET 15MG 30 |
01/01/2022 |
136.20 |
1585.40 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000219 |
Teva Women's Health, Inc. |
03/31/2022 |
51285036601 |
TREXALL TABLET 5MG 30 |
01/01/2022 |
45.40 |
528.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000219 |
Teva Women's Health, Inc. |
03/31/2022 |
51285036701 |
TREXALL TABLET 7.5MG 30 |
01/01/2022 |
68.10 |
792.70 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000219 |
Teva Women's Health, Inc. |
03/31/2022 |
51285004001 |
ZIAC TABLET 10MG/6.25MG 30 |
01/01/2022 |
21.20 |
247.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000219 |
Teva Women's Health, Inc. |
03/31/2022 |
51285004702 |
ZIAC TABLET 2.5MG/6.25MG 100 |
01/01/2022 |
70.70 |
823.20 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000219 |
Teva Women's Health, Inc. |
03/31/2022 |
51285005002 |
ZIAC TABLET 5MG/6.25MG 100 |
01/01/2022 |
70.70 |
823.20 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; product was not acquired within the previous five years. |
Rx0000134 |
Therakos, Inc. |
03/31/2022 |
64067021601 |
UVADEX (Methoxsalen) STERILE SOLUTION, 20 mcg/ML |
01/01/2022 |
576.00 |
6974.00 |
None |
Single Source Drug |
None |
1 |
This price is not reflective of discounts available to customers. This increase is the result of increased costs and other financial commitments of the company, including the recent launch of a new biologic therapy to treat adults with deep partial-thickness burns and the potential launch of another therapy later this year. Mallinckrodt continues to invest in innovation that brings value to patients, providers, and the U.S. healthcare system through research and development, quality manufacturing, as well as through patient education and disease awareness. |
None |
This price is not reflective of discounts available to customers. This increase is the result of increased costs and other financial commitments of the company, including the recent launch of a new biologic therapy to treat adults with deep partial-thickness burns and the potential launch of another therapy later this year. Mallinckrodt continues to invest in innovation that brings value to patients, providers, and the U.S. healthcare system through research and development, quality manufacturing, as well as through patient education and disease awareness. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This price information is reflective of the case unit of sale of the product. Uvadex is used only for extracorporeal photopheresis (ECP) therapy and is administered by a healthcare professional in a clinical setting. |
Rx0000057 |
Theratechnologies Inc. |
03/31/2022 |
62064024130 |
EGRIFTA SV 2MG LYO PWD 30/PAC |
01/01/2022 |
367.00 |
6491.00 |
05/01/2023 |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Theratechnologies considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain. |
Rx0000057 |
Theratechnologies Inc. |
03/31/2022 |
62064012202 |
TROGARZO 150MG/ML 1.33ML SDV 2/PAC |
01/01/2022 |
127.00 |
2676.00 |
04/01/2030 |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Theratechnologies considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain. |
Rx0000183 |
Tris Pharma, Inc |
03/31/2022 |
27808010201 |
Dyanavel XR 2.5mg/mL Suspension 464mL Bottle |
01/03/2022 |
38.54 |
1341.99 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |